Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2023 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

Assigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin...
February 21, 2023 07:22 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
January 24, 2023 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 ...
January 04, 2023 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1 2023 NDA Resubmission for VP-102 ...
November 07, 2022 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa.,...
August 31, 2022 16:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
August 11, 2022 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun...
August 01, 2022 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics...
June 29, 2022 21:23 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Pricing of Public Offering of Common Stock

WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
June 29, 2022 16:01 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Proposed Public Offering of Common Stock

WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...